Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  January 2019  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
   1  2  3  4  5  6
  7  810111213
141517181920
212224252627
282931   

Latest IDIGH Publications

  1. Désilets, L., Fernet, M., Otis, J., Cousineau, M.-M., Massie, L., De Pokomandy, A. & Nengeh Mensah, M.
    (2020)
    .
    Trauma-Informed Practices to Address Intersections Between HIV and Intimate Partner Violence Among Women: Perspective of Community Service Providers
    .
    The Journal of the Association of Nurses in AIDS Care : JANAC
  2. Rudnick, W., Science, M., Thirion, D. J. G., Abdesselam, K., Choi, K. B., Pelude, L., Amaratunga, K., Comeau, J. L., Dalton, B., Delport, J., Dhami, R., Embree, J., Émond, Y., Evans, G., Frenette, C., Fryters, S., German, G., Grant, J. M., Happe, J., Katz, K., Kibsey, P., Kosar, J., Langley, J. M., Lee, B. E., Lefebvre, M.-A., Leis, J. A., McGeer, A., Neville, H. L., Simor, A., Slayter, K., Suh, K. N., Tse-Chang, A., Weiss, K., Conly, J. & Canadian Nosocomial Infection Surveillance Program.
    (2020)
    .
    Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016
    .
    Antimicrobial resistance and infection control
    ,
    vol
    .
    9
    ,
    p
    .
    32
    .
  3. Guaraldi, G., Maurice, J. B., Marzolini, C., Monteith, K., Milic, J., Tsochatzis, E., Bhagani, S., Morse, C. G., Price, J. C., Ingiliz, P., Lemoine, M., Sebastiani, G. & SHIVER Network.
    (2020)
    .
    New drugs for non-alcoholic steatohepatitis and HIV infection: great expectations with a great absent?
    .
    Hepatology (Baltimore, Md.)
  4. Roy Cardinal, M.-H., Durand, M., Chartrand-Lefebvre, C., Fortin, C., Baril, J.-G., Trottier, B., Routy, J.-P., Soulez, G., Tremblay, C. & Cloutier, G.
    (2020)
    .
    Increased carotid artery wall stiffness and plaque prevalence in HIV infected patients measured with ultrasound elastography
    .
    European radiology
  5. Taylor, R. S., Taylor, R. J., Bayliss, S., Hagstrom, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., Shlomai, A., Sebastiani, G., Seko, Y., Bhala, N., Younossi, Z. M., Anstee, Q. M., McPherson, S., Newsome, P. N. & Collaborators.
    (2020)
    .
    Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
    .
    Gastroenterology
More publications